Introduction
Indocyanine Green (ICG) is a dye used in the diagnosis and treatment of various diseases, especially ophthalmology, neurosurgery, and liver diseases. The dye consists of a tricarbocyanine, an anionic dye, which is composed of a fullerene, a carboxylic acid, and a sulfonate group. It is a fluorescent dye with a visible green color and is used in various medical procedures. The increasing usage of ICG in medical procedures, such as in ophthalmology, neurosurgery, and liver diseases, is driving the ICG market growth.
Market Dynamics
The increasing prevalence of ophthalmology, neurosurgery, and liver diseases has surged the demand for ICG. The growing demand for ICG is also attributed to its ability to increase the accuracy of diagnosis and treatment. In addition, the surge in the number of medical procedures, such as angiography, arteriography, and endoscopy, is also driving the growth of the ICG market. Furthermore, the increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth.
On the other hand, stringent government regulations regarding the use of ICG in medical procedures are expected to restrain the market growth. Furthermore, the increasing cost of ICG is also expected to hamper the market growth.
Market Analysis
The global ICG market is segmented into type and application. On the basis of type, the market is divided into type I and type II. The type I segment is expected to account for the largest share of the market during the forecast period, owing to its increasing usage in medical procedures, such as angiography, arteriography, and endoscopy.
Based on application, the market is categorized into ophthalmology, neurosurgery, and liver diseases. The ophthalmology segment is expected to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology diseases, such as cataract and glaucoma.
On the regional front, the global ICG market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America is anticipated to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases in the region. The market in Asia-Pacific is expected to be the fastest-growing during the forecast period, owing to the increasing investments in research and development for the development of novel ICG formulations.
Future Trends
The ICG market is expected to grow at a steady pace during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases. In addition, the increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth.
Market Opportunities
The increasing prevalence of ophthalmology, neurosurgery, and liver diseases is expected to provide lucrative opportunities for the growth of the ICG market. Furthermore, the increasing investments in research and development for the development of novel ICG formulations are expected to open new avenues for the market growth.
Key Regulations
The usage of ICG for medical procedures is regulated by the U.S. Food and Drug Administration (FDA). The FDA has set certain standards for the usage of ICG in medical procedures. These standards include the use of approved ICG formulations, the proper labeling of products, and the adherence to safety standards.
Segmental Overview
The global ICG market is segmented into type and application. On the basis of type, the market is divided into type I and type II. The type I segment is expected to account for the largest share of the market during the forecast period, owing to its increasing usage in medical procedures, such as angiography, arteriography, and endoscopy.
Based on application, the market is categorized into ophthalmology, neurosurgery, and liver diseases. The ophthalmology segment is expected to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology diseases, such as cataract and glaucoma.
Market Scenario
The ICG market is expected to register healthy growth during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases. The increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth.
Growth Opportunities by Region
North America is anticipated to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases in the region. The market in Asia-Pacific is expected to be the fastest-growing during the forecast period, owing to the increasing investments in research and development for the development of novel ICG formulations.
Qualitative Insights
The key players in the ICG market are Akorn, PULSION Medical Systems AG, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical Co.Ltd., Aurolab, Yichuang, and Eisaialso. The companies are focusing on product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities to gain a competitive edge in the market.
For instance, in 20XX, PULSION Medical Systems AG launched its new product, HemoFlow ICG, a non-invasive cardiac output monitoring system which uses ICG for measuring cardiac output. Similarly, in 20XX, Daiichi Sankyo Company launched its new product, ICG-001, a drug-eluting stent coated with ICG.
Porter’s Five Force Analysis
The bargaining power of suppliers in the ICG market is high, as there are only a few suppliers in the market. Furthermore, the suppliers have a strong negotiating power over the prices of ICG, as the demand for ICG is increasing.
The bargaining power of buyers in the ICG market is medium, as the buyers have limited options to choose from. Furthermore, the buyers in the market are price-sensitive, due to the increasing cost of ICG.
The threat of new entrants in the ICG market is low, as the market is dominated by a few players and it is difficult for new entrants to break into the market.
The threat of substitutes in the ICG market is low, as there are no substitutes available for ICG.
The intensity of rivalry in the ICG market is high, as there are a few established players in the market. The players are focusing on product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities to gain a competitive edge in the market.
Strategies Adopted
The key players in the ICG market are Akorn, PULSION Medical Systems AG, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical Co.Ltd., Aurolab, Yichuang, and Eisaialso. The companies have adopted various strategies, such as product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities, to gain a competitive edge in the market.
For instance, in 20XX, PULSION Medical Systems AG launched its new product, HemoFlow ICG, a non-invasive cardiac output monitoring system which uses ICG for measuring cardiac output. Similarly, in 20XX, Daiichi Sankyo Company launched its new product, ICG-001, a drug-eluting stent coated with ICG.
In addition, Akorn announced its partnership with Eisaialso to develop new ICG products in 20XX. The partnership is aimed at expanding the product portfolio of Akorn in the ICG market.
The 5 new companies in the ICG market are Alcon, Optovue, Heidelberg Engineering, ZEISS, and Topcon. These companies have adopted various strategies, such as product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities, to gain a competitive edge in the market.
For instance, in 20XX, Optovue launched its new product, the Optovue iVue OCT Angiography. The product is used for the imaging and assessment of retinal and choroidal vessels using ICG. Similarly, in 20XX, Heidelberg Engineering announced its partnership with SERB to develop new ICG products. The partnership is aimed at expanding the product portfolio of Heidelberg Engineering in the ICG market.
The ICG market is expected to register healthy growth during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases. The increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth. North America is anticipated to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases in the region. The key players in the ICG market are Akorn, PULSION Medical Systems AG, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical Co.Ltd., Aurolab, Yichuang, and Eisaialso. The companies have adopted various strategies, such as product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities, to gain a competitive edge in the market.
Indocyanine Green (ICG) is a dye used in the diagnosis and treatment of various diseases, especially ophthalmology, neurosurgery, and liver diseases. The dye consists of a tricarbocyanine, an anionic dye, which is composed of a fullerene, a carboxylic acid, and a sulfonate group. It is a fluorescent dye with a visible green color and is used in various medical procedures. The increasing usage of ICG in medical procedures, such as in ophthalmology, neurosurgery, and liver diseases, is driving the ICG market growth.
Market Dynamics
The increasing prevalence of ophthalmology, neurosurgery, and liver diseases has surged the demand for ICG. The growing demand for ICG is also attributed to its ability to increase the accuracy of diagnosis and treatment. In addition, the surge in the number of medical procedures, such as angiography, arteriography, and endoscopy, is also driving the growth of the ICG market. Furthermore, the increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth.
On the other hand, stringent government regulations regarding the use of ICG in medical procedures are expected to restrain the market growth. Furthermore, the increasing cost of ICG is also expected to hamper the market growth.
Market Analysis
The global ICG market is segmented into type and application. On the basis of type, the market is divided into type I and type II. The type I segment is expected to account for the largest share of the market during the forecast period, owing to its increasing usage in medical procedures, such as angiography, arteriography, and endoscopy.
Based on application, the market is categorized into ophthalmology, neurosurgery, and liver diseases. The ophthalmology segment is expected to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology diseases, such as cataract and glaucoma.
On the regional front, the global ICG market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America is anticipated to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases in the region. The market in Asia-Pacific is expected to be the fastest-growing during the forecast period, owing to the increasing investments in research and development for the development of novel ICG formulations.
Future Trends
The ICG market is expected to grow at a steady pace during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases. In addition, the increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth.
Market Opportunities
The increasing prevalence of ophthalmology, neurosurgery, and liver diseases is expected to provide lucrative opportunities for the growth of the ICG market. Furthermore, the increasing investments in research and development for the development of novel ICG formulations are expected to open new avenues for the market growth.
Key Regulations
The usage of ICG for medical procedures is regulated by the U.S. Food and Drug Administration (FDA). The FDA has set certain standards for the usage of ICG in medical procedures. These standards include the use of approved ICG formulations, the proper labeling of products, and the adherence to safety standards.
Segmental Overview
The global ICG market is segmented into type and application. On the basis of type, the market is divided into type I and type II. The type I segment is expected to account for the largest share of the market during the forecast period, owing to its increasing usage in medical procedures, such as angiography, arteriography, and endoscopy.
Based on application, the market is categorized into ophthalmology, neurosurgery, and liver diseases. The ophthalmology segment is expected to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology diseases, such as cataract and glaucoma.
Market Scenario
The ICG market is expected to register healthy growth during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases. The increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth.
Growth Opportunities by Region
North America is anticipated to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases in the region. The market in Asia-Pacific is expected to be the fastest-growing during the forecast period, owing to the increasing investments in research and development for the development of novel ICG formulations.
Qualitative Insights
The key players in the ICG market are Akorn, PULSION Medical Systems AG, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical Co.Ltd., Aurolab, Yichuang, and Eisaialso. The companies are focusing on product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities to gain a competitive edge in the market.
For instance, in 20XX, PULSION Medical Systems AG launched its new product, HemoFlow ICG, a non-invasive cardiac output monitoring system which uses ICG for measuring cardiac output. Similarly, in 20XX, Daiichi Sankyo Company launched its new product, ICG-001, a drug-eluting stent coated with ICG.
Porter’s Five Force Analysis
The bargaining power of suppliers in the ICG market is high, as there are only a few suppliers in the market. Furthermore, the suppliers have a strong negotiating power over the prices of ICG, as the demand for ICG is increasing.
The bargaining power of buyers in the ICG market is medium, as the buyers have limited options to choose from. Furthermore, the buyers in the market are price-sensitive, due to the increasing cost of ICG.
The threat of new entrants in the ICG market is low, as the market is dominated by a few players and it is difficult for new entrants to break into the market.
The threat of substitutes in the ICG market is low, as there are no substitutes available for ICG.
The intensity of rivalry in the ICG market is high, as there are a few established players in the market. The players are focusing on product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities to gain a competitive edge in the market.
Strategies Adopted
The key players in the ICG market are Akorn, PULSION Medical Systems AG, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical Co.Ltd., Aurolab, Yichuang, and Eisaialso. The companies have adopted various strategies, such as product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities, to gain a competitive edge in the market.
For instance, in 20XX, PULSION Medical Systems AG launched its new product, HemoFlow ICG, a non-invasive cardiac output monitoring system which uses ICG for measuring cardiac output. Similarly, in 20XX, Daiichi Sankyo Company launched its new product, ICG-001, a drug-eluting stent coated with ICG.
In addition, Akorn announced its partnership with Eisaialso to develop new ICG products in 20XX. The partnership is aimed at expanding the product portfolio of Akorn in the ICG market.
The 5 new companies in the ICG market are Alcon, Optovue, Heidelberg Engineering, ZEISS, and Topcon. These companies have adopted various strategies, such as product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities, to gain a competitive edge in the market.
For instance, in 20XX, Optovue launched its new product, the Optovue iVue OCT Angiography. The product is used for the imaging and assessment of retinal and choroidal vessels using ICG. Similarly, in 20XX, Heidelberg Engineering announced its partnership with SERB to develop new ICG products. The partnership is aimed at expanding the product portfolio of Heidelberg Engineering in the ICG market.
The ICG market is expected to register healthy growth during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases. The increasing investments in research and development for the development of novel ICG formulations are expected to further fuel the market growth. North America is anticipated to dominate the market during the forecast period, owing to the increasing prevalence of ophthalmology, neurosurgery, and liver diseases in the region. The key players in the ICG market are Akorn, PULSION Medical Systems AG, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical Co.Ltd., Aurolab, Yichuang, and Eisaialso. The companies have adopted various strategies, such as product/service launches, acquisitions, business expansions, partnerships, investments, and research and development activities, to gain a competitive edge in the market.
Key Benefits of the Report
- This study presents the analytical depiction of the Indocyanine Green Market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Indocyanine Green Market share.
- The current market is quantitatively analyzed to highlight the Indocyanine Green Market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed Indocyanine Green Market analysis based on competitive intensity and how the competition will take shape in coming years
Indocyanine Green Market Report Highlights
| Aspects | Details |
 By Types |
|
 By Applications |
|
 By Region |
|
 Key Market Players | Eisai, PULSION Medical Systems AG, Daiichi Sankyo Company, Aurolab, Santen Pharmaceutical Co.Ltd., Diagnostic Green, Yichuang, Akorn, SERB |
Loading Table Of Content...
